Nuvo Research Inc. Announces 2012 Fourth Quarter & Year-End Results

Published: Mar 28, 2013

MISSISSAUGA, ON, March 27, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the fourth quarter and year ended December 31, 2012.

Back to news